There are 2789 resources available
985P - Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors
Presenter: Thorsten Goetze
Session: ePoster Display
986P - Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice
Presenter: Toshihide Nishibata
Session: ePoster Display
987P - A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
Presenter: toshifumi obonai
Session: ePoster Display
988P - Ocular complications of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: A multi-center prospective observational cohort study
Presenter: Kevin Sheng-Kai Ma
Session: ePoster Display
989P - Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)
Presenter: Sofia Genta
Session: ePoster Display
990P - Endocrine immune-related adverse events (irAEs) of combined immunotherapy in solid tumors: Systematic review and meta-analysis
Presenter: Nikolaos Tsoukalas
Session: ePoster Display
991P - Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
Presenter: Thierry André
Session: ePoster Display
992P - Pan-cancer T-cell priming transcriptomic markers reveals interpatient immunomic heterogeneity independent of histologic type
Presenter: Hirotakka Miyashita
Session: ePoster Display
993P - Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
Presenter: Saulo Silva
Session: ePoster Display
994P - PCR-based analysis of PD-L1 RNA expression in lung cancer: Comparison with commonly utilized immunohistochemical assays
Presenter: Evgeny Imyanitov
Session: ePoster Display